Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.

ABSTRACT:

Importance

Acute promyelocytic leukemia (APL) is an acute illness that presents with cytopenia, infections, and disseminated intravascular coagulation. Achieving remission has been shown to make a major difference in patient outcomes; however, early death rates in the first month have been as high as 30% due to acute presentation, comorbidities, the rarity of APL, and clinician inexperience.

Objective

To develop treatment strategies that would decrease estimated 1-month mortality from 30% to below 15%.

Design, setting, and participants

In this nonrandomized clinical trial, a treatment algorithm that focused on supportive care was used to prevent early death in patients with APL treated at academic and community health centers between August 2017 and July 2021. Because

SUBMITTER: Jillella AP 

PROVIDER: S-EPMC11869096 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature